Μετάβαση στο περιεχόμενο

ΕτικέταGlaxoSmithKline

GSK’s Nucala Shows Superior Benefits to Other IL-5 Inhibitors in Asthma, But Fails as a COPD Drug

Days after receiving a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on COPD treatment, GlaxoSmithKline released data that showed the same medication was a superior treatment in severe … Continue Reading GSK’s Nucala Shows Superior Benefits to Other IL-5 Inhibitors in Asthma, But Fails as a COPD Drug